Compare companies
Put any US companies we track side by side — SEC-sourced financials, ratios, forensic scores, and our Quality Score. Add up to four. No market price, no paywall.
HALOZYME THERAPEUTICS, INC.
| Metric | HALOZYME THERAPEUTICS, INC. HALOOther |
|---|---|
| Quality Score | 72 / 100 |
| Revenue (latest) | $1.40B |
| Net income (latest) | $317M |
| Operating margin | 33.6% |
| Net margin | 22.7% |
| Return on equity | 649.2% |
| Return on assets | 12.5% |
| Return on capital (ROCE) | 20.0% |
| Debt / equity | 50.73× |
| Revenue growth (YoY) | 37.6% |
| Altman Z″ (distress) | 3.02 |
| Accruals / assets | −13.3% |
Latest reported figures from each company's own SEC filings (XBRL) plus our derived scores. Blank where a line item isn't cleanly tagged — never estimated. Descriptive factors, not advice. Open a company for its full multi-year history.